RegulatoryCompany release
FDA approves Novartis' Cosentyx 150 mg for polymyalgia rheumatica
Novartis Pharma AG · Tue 17 Nov 2026
Novartis says Cosentyx is the first and only anti-IL-17 biologic cleared in the US for polymyalgia rheumatica, giving adults an option beyond long-term corticosteroids.
The US Food and Drug Administration has approved Novartis' Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica (PMR), the company announced on 17 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release: Novartis Pharma AG ↗
Article written by VigiEye from the official source (Novartis Pharma AG). Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
EEA Joint Committee extends three EU feed additive rules to Iceland and Norway
🇪🇺 EUR-Lex · Thu 19 Nov 2026
Health Canada lists Class II recall of Stryker's Blueprint shoulder-planning software over two bugs
🇨🇦 Health Canada · Wed 18 Nov 2026
FDA approves Infilbray, first treatment for neurological symptoms of Type 3 Gaucher disease
🇺🇸 FDA · Wed 18 Nov 2026
INFARMED lifts suspension of Limeciclina Atral 408 mg capsules after bioequivalence shown
🇵🇹 INFARMED · Wed 18 Nov 2026
Commission publishes minutes of SCHEER working group meeting on brain stimulators
🇪🇺 European Commission (DG SANTE) · Wed 18 Nov 2026
AIFA reminds sponsors how to pay Annual Safety Report evaluation fee
🇮🇹 AIFA · Wed 18 Nov 2026